Robert, a interesting question !
------------------------------
Per Holse Mygind
Director, Clinical Biomarkers & Immunogenicity
Ascendis Pharma
Hellerup
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------
Original Message:
Sent: 02-04-2024 20:04
From: Robert Kubiak
Subject: Artificial Intelligence for Immunogenicity Assessments
I was wondering if any of you have experience with using AI/ML to deliver and/or assess ADA data? Not to forecast potential immunogenicity but to assist in the delivery and/or interpretation of clinical study results and overall immunogenic profile of a biotherapeutic?
------------------------------
Robert Kubiak PhD
Associate Director, R&D
AstraZeneca PLC
Gaithersburg MD
[email protected]
Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------